IP Verse

Antibody Which Is Directed Against Galectin-9 And Is An Inhibitor Of The Suppressor Activity Of Regulatory T Lymphocytes - EP3152234

The patent EP3152234 was granted to Cellvax on Jun 26, 2024. The application was originally filed on Jun 5, 2015 under application number EP15732846A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3152234

CELLVAX
Application Number
EP15732846A
Filing Date
Jun 5, 2015
Status
Patent Maintained As Amended
May 24, 2024
Grant Date
Jun 26, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEApr 8, 2021HOFFMANN EITLEWITHDRAWN

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0173494
DESCRIPTIONEP1586325
DESCRIPTIONUS5882877
DESCRIPTIONWO9514785
DESCRIPTIONWO9622378
DESCRIPTIONWO9845322
INTERNATIONAL-SEARCH-REPORTWO2010084999
INTERNATIONAL-SEARCH-REPORTWO2012177788
OPPOSITIONUS8329660
OPPOSITIONWO2010084999
OPPOSITIONWO2014144600
OPPOSITIONWO2016073299
OPPOSITIONWO2021139682
OTHERUS8329660
OTHERWO2010084999

Non-Patent Literature (NPL) Citations (76) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Aerts Joachim G., Hegmans Joost P., "Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer", Cancer Research, American Association for Cancer Research, US, US, (20130415), vol. 73, no. 8, doi:10.1158/0008-5472.CAN-12-3932, ISSN 0008-5472, pages 2381 - 2388
OPPOSITION- Akimova Tatiana, Hancock Wayne W., "How little is known about the role of human FOXP3+ Tregs in tumors", Expert Opinion on therapeutic targets, Informa Healthcare, UK, UK , (20180803), vol. 22, no. 8, doi:10.1080/14728222.2018.1499728, ISSN 1472-8222, pages 655 - 658
OPPOSITION- Akimova Tatiana, Hancock Wayne W., "How little is known about the role of human FOXP3+ Tregs in tumors", Expert Opinion on therapeutic targets, Informa Healthcare, UK, UK , (20180803), vol. 22, no. 8, doi:10.1080/14728222.2018.1499728, ISSN 1472-8222, pages 655 - 658, XP093119760
OPPOSITION- Andrea Ladányi, "A tumort infiltráló immunsejtek prognosztikai értéke melanómában", Magyar Onkológia, (20130101), pages 85 - 95, Magyar Onkológia, URL: https://huon.hu/2013/57/2/0085/0085a.pdf, (20210511), XP055803613
OPPOSITION- Avalos-Martinez Claudia E, "Measurement of suppressor activity of T CD 4+ CD 25+ T reg cells using bromodeoxyuridine incorporation assay", Immunol Invest., (20130101), vol. 42, no. 4, pages 369 - 381
OPPOSITION- Avalos-Martinez Claudia E, "Measurement of suppressor activity of T CD 4+ CD 25+ T reg cells using bromodeoxyuridine incorporation assay", Immunol Invest., (20130101), vol. 42, no. 4, pages 369 - 381, XP055803547
OPPOSITION- BARJON, "Caractérisation biochimique et fonctionnelle de nouveaux anticorps monoclonaux anti-galectine-9 en vue d'applications diagnostiques et thérapeutiques", Thèse de doctorat en Cancérologie, Immunologie, Biologie cellulaire, Biochimie, (20130205), pages 1 - 128
OPPOSITION- BARJON et al., "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", Infectious Agents and Cancer, (20120000), vol. 7, no. 1, doi:10.1186/1750-9378-7-16, pages 1 - 11
OPPOSITION- Binding experiments with anti- Gal- 9 antibodies
OPPOSITION- CEDENO-LAURENT et al., "Galectins and their ligands: negative regulators of anti-tumor immunity", Glycoconj J., (20120000), vol. 29, no. 8-9, doi:10.1007/s10719-012-9379-0, pages 619 - 625
OPPOSITION- Comparative tests filed by the Patentees Prior to grant
OPPOSITION- Cuellar Luis Ernesto et al, "Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience", Infectious Agents and Cancer, (20181201), vol. 13, no. 1, doi:10.1186/s13027-018-0200-y
OPPOSITION- Database references confirming that the Barjon Doctoral Thesis was published in 2013
OPPOSITION- English translation of D27 (machine translation by google translate)
OPPOSITION- Evidence that 1G3 was commercially available at least by May 2015
OPPOSITION- FUJIHARA et al., "Galectin-9 in Cancer Therapy", Recent Pat Endocr Metab Immune Drug Discov., (20130000), vol. 7, no. 2, doi:10.2174/1872214811307020006, pages 130 - 7
OPPOSITION- Fujita Koji, Et Al, "Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo", International journal of oncology, Demetrios A. Spandidos Ed. & Pub, GR, GR, (20150601), vol. 46, no. 6, doi:10.3892/ijo.2015.2941, ISSN 1019-6439, pages 2419 - 2430
OPPOSITION- Gooden M J M, De Bock G H, Leffers N, Daemen T, Nijman H W, "The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis", British Journal of Cancer, Nature Publishing Group, GB, GB, (20110601), vol. 105, no. 1, doi:10.1038/bjc.2011.189, ISSN 0007-0920, pages 93 - 103
OPPOSITION- Hassen Kared, Fabre Thomas, Bédard Nathalie, Bruneau Julie, Shoukry Naglaa H., "Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C", PLoS Pathogens, vol. 9, no. 6, doi:10.1371/journal.ppat.1003422, pages e1003422 - e1003422-18
OPPOSITION- Heusschen Roy, Et Al, "Galectin-9 in tumor biology: A jack of multiple trades", Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, (20130101), vol. 1836, pages 177 - 185
OPPOSITION- Heusschen Roy, Et Al, "Galectin-9 in tumor biology: A jack of multiple trades", Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, (20130101), vol. 1836, pages 177 - 185, XP055803466
OPPOSITION- IDS tiled by Patentee in the US admitting that the Barjon Doctoral Thesis was published in 2013
OPPOSITION- IRIE et al., "Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer", Clin Cancer Res., (20050000), vol. 11, no. 8, doi:10.1158/1078-0432.CCR-04-0861, pages 2962 - 8
OPPOSITION- Jiang Jing, Et Al, "Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer", PLoS ONE, (20131201), vol. 8, no. 12, doi:10.1371/journal.pone.0081799, page e81799
OPPOSITION- JU et al., "The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis", Molecular Immunology, (20140000), vol. 58, no. 1, doi:10.1016/j.molimm.2013.11.001, pages 85 - 91
OPPOSITION- KADOWAKI et al., "Galectin-9 prolongs the survival of septic mice by expanding tim-3-expressing natural killer T cells and PDCA-1+ CDllc+macrophages", Crit Care, (20130000), vol. 17, no. 6, doi:10.1186/cc13147, pages 1 - 11
OPPOSITION- KLIBI et al., "Blood diffusion and Th 1-suppressive effects of galectin-9- containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells", Blood, (20090000), vol. 113, no. 9, doi:10.1182/blood-2008-02-, pages 1957 - 66
OPPOSITION- Kobayashi T, Et Al, "Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways", Leukemia, Stockton Press, London, London, (20100401), vol. 24, no. 4, doi:10.1038/leu.2010.25, ISSN 0887-6924, pages 843 - 850
OPPOSITION- LHUILLIER, "Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9", PLoS ONE, (20180000), vol. 13, no. 9, doi:10.1371/journal.pone.0202512, pages 1 - 23
OPPOSITION- Liberal Rodrigo et al, "The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway", Hepatology, John Wiley & Sons, Inc., US, US, (20120801), vol. 56, no. 2, doi:10.1002/hep.25682, ISSN 0270-9139, pages 677 - 686
OPPOSITION- MCMURCHY et al., "Suppression assays with human T regulatory cells: A technical guide", Eur. J. Immunol., (20120000), vol. 42, no. 1, doi:10.1002/eji.201141651, pages 27 - 34
OPPOSITION- Mouglakakos Dimitrios, Et Al, "Regulatory T Cells in Cancer", Advances in Cancer Research, (20100101), vol. 107, pages 57 - 117
OPPOSITION- Mouglakakos Dimitrios, Et Al, "Regulatory T Cells in Cancer", Advances in Cancer Research, (20100101), vol. 107, pages 57 - 117, XP055803461
OPPOSITION- Nobumoto A., Et Al, "Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices", GLYCOBIOLOGY, Oxford University Press, US, US, (20080101), vol. 18, no. 9, doi:10.1093/glycob/cwn062, ISSN 0959-6658, pages 735 - 744
OPPOSITION- NPC xenograft experiments with antibodies 1G3 and 2E12 in mouse
OPPOSITION- Poster by Margall II
OPPOSITION- Proliferation experiments with anti- Gal -9 antibodies
OPPOSITION- RABINOVICH et al., "Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer", Immunity, (20120000), vol. 36, no. 3, doi:10.1016/j.immuni.2012.03.004, pages 322 - 35
OPPOSITION- Rabinovich G. A., Liu F.-T., Hirashima M., Anderson A., "An Emerging Role for Galectins in Tuning the Immune Response: Lessons from Experimental Models of Inflammatory Disease, Autoimmunity and Cancer", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, GB, (20070801), vol. 66, no. 2-3, doi:10.1111/j.1365-3083.2007.01986.x, ISSN 0300-9475, pages 143 - 158
OPPOSITION- SAKAGUCHI, "Naturally arising Foxp3-expressing CD 25+ CD 4+ regulatory T cells in immunological tolerance to self and non-self", Nature Immunology, (20050000), vol. 6, no. 4, doi:10.1038/ni1178, pages 345 - 52
OPPOSITION- SAKAGUCHI, "Regulatory T Cells: Key Controllers of Immunologic Self- Tolerance", Cell, (20000000), vol. 101, no. 5, doi:10.1016/S0092-8674(00)80856-9, pages 455 - 8
OPPOSITION- Sun Qiqing, Et Al, "Prognostic and diagnostic signifcance of galectins in pancreatic cancer: a systematic review and meta-analysis", Cancer Cell International, (20191201), vol. 19, no. 309, doi:10.1186/s12935-019-1025-5, pages 1 - 14
OPPOSITION- TAAMS et al., "Human anergic/suppressive CD 4+ CD 25+ T cells: a highly differentiated and apoptosis-prone population", Eur. J. Immunol., (20010000), vol. 31, doi:10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P, pages 1122 - 1131
OPPOSITION- Töpfer Katrin et al, "Tumor Evasion from T Cell Surveillance", Journal of Biomedicine and Biotechnology, (20110101), vol. 2011, doi:10.1155/2011/918471, ISSN 1110-7243, pages 1 - 19
OPPOSITION- Translation D27
OPPOSITION- WANG et al., "Tim-3-Galectin-9 pathway involves the suppression induced by CD 4+ CD 25+ regulatory T cells", Immunobiology, (20090000), vol. 214, no. 5, doi:10.1016/j.imbio.2008.10.007, pages 342 - 9
OPPOSITION- Wang Kai, Chen Zhen, Wu Rongzu, Yin Jun, Fan Min, Xu Xianlin, "Prognostic Role of High Gal-9 Expression in Solid Tumours: a Meta-Analysis", Cellular Physiology and Biochemistry, Karger Basel, CH, CH, (20180101), vol. 45, no. 3, doi:10.1159/000487294, ISSN 1015-8987, pages 993 - 1002
OPPOSITION- Yang Jiaxing, Zhu Lin, Cai Yong, Suo Jian, Jin Jingji, "Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer", International journal of oncology, Demetrios A. Spandidos Ed. & Pub, GR, GR, (20140901), vol. 45, no. 3, doi:10.3892/ijo.2014.2494, ISSN 1019-6439, pages 1313 - 1320
OPPOSITION- TAAMS et al., "Human anergic/suppressive CD 4+ CD 25+ T cells: a highly differentiated and apoptosis-prone population", Eur. J. Immunol., (20010000), vol. 31, doi:10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P, pages 1122 - 1131, XP055683382
OPPOSITION- MCMURCHY et al., "Suppression assays with human T regulatory cells: A technical guide", Eur. J. Immunol., (20120000), vol. 42, no. 1, doi:10.1002/eji.201141651, pages 27 - 34, XP055142943
OPPOSITION- Liberal Rodrigo et al, "The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway", Hepatology, John Wiley & Sons, Inc., US, US, (20120801), vol. 56, no. 2, doi:10.1002/hep.25682, ISSN 0270-9139, pages 677 - 686, XP055803638
OPPOSITION- CEDENO-LAURENT et al., "Galectins and their ligands: negative regulators of anti-tumor immunity", Glycoconj J., (20120000), vol. 29, no. 8-9, doi:10.1007/s10719-012-9379-0, pages 619 - 625, XP035124722
OPPOSITION- WANG et al., "Tim-3-Galectin-9 pathway involves the suppression induced by CD 4+ CD 25+ regulatory T cells", Immunobiology, (20090000), vol. 214, no. 5, doi:10.1016/j.imbio.2008.10.007, pages 342 - 9, XP026037212
OPPOSITION- RABINOVICH et al., "Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer", Immunity, (20120000), vol. 36, no. 3, doi:10.1016/j.immuni.2012.03.004, pages 322 - 35, XP028475161
OPPOSITION- JU et al., "The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis", Molecular Immunology, (20140000), vol. 58, no. 1, doi:10.1016/j.molimm.2013.11.001, pages 85 - 91, XP028548619
OPPOSITION- SAKAGUCHI, "Regulatory T Cells: Key Controllers of Immunologic Self- Tolerance", Cell, (20000000), vol. 101, no. 5, doi:10.1016/S0092-8674(00)80856-9, pages 455 - 8, XP003025450
OPPOSITION- Gooden M J M, De Bock G H, Leffers N, Daemen T, Nijman H W, "The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis", British Journal of Cancer, Nature Publishing Group, GB, GB, (20110601), vol. 105, no. 1, doi:10.1038/bjc.2011.189, ISSN 0007-0920, pages 93 - 103, XP055803621
OPPOSITION- Kobayashi T, Et Al, "Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways", Leukemia, Stockton Press, London, London, (20100401), vol. 24, no. 4, doi:10.1038/leu.2010.25, ISSN 0887-6924, pages 843 - 850, XP055803648
OPPOSITION- SAKAGUCHI, "Naturally arising Foxp3-expressing CD 25+ CD 4+ regulatory T cells in immunological tolerance to self and non-self", Nature Immunology, (20050000), vol. 6, no. 4, doi:10.1038/ni1178, pages 345 - 52, XP002394639
OPPOSITION- Nobumoto A., Et Al, "Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices", GLYCOBIOLOGY, Oxford University Press, US, US, (20080101), vol. 18, no. 9, doi:10.1093/glycob/cwn062, ISSN 0959-6658, pages 735 - 744, XP055803643
OPPOSITION- Rabinovich G. A., Liu F.-T., Hirashima M., Anderson A., "An Emerging Role for Galectins in Tuning the Immune Response: Lessons from Experimental Models of Inflammatory Disease, Autoimmunity and Cancer", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, GB, (20070801), vol. 66, no. 2-3, doi:10.1111/j.1365-3083.2007.01986.x, ISSN 0300-9475, pages 143 - 158, XP055803633
OPPOSITION- Töpfer Katrin et al, "Tumor Evasion from T Cell Surveillance", Journal of Biomedicine and Biotechnology, (20110101), vol. 2011, doi:10.1155/2011/918471, ISSN 1110-7243, pages 1 - 19, XP055803537
OPPOSITION- Aerts Joachim G., Hegmans Joost P., "Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer", Cancer Research, American Association for Cancer Research, US, US, (20130415), vol. 73, no. 8, doi:10.1158/0008-5472.CAN-12-3932, ISSN 0008-5472, pages 2381 - 2388, XP055803539
OPPOSITION- IRIE et al., "Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer", Clin Cancer Res., (20050000), vol. 11, no. 8, doi:10.1158/1078-0432.CCR-04-0861, pages 2962 - 8, XP002432614
OPPOSITION- Wang Kai, Chen Zhen, Wu Rongzu, Yin Jun, Fan Min, Xu Xianlin, "Prognostic Role of High Gal-9 Expression in Solid Tumours: a Meta-Analysis", Cellular Physiology and Biochemistry, Karger Basel, CH, CH, (20180101), vol. 45, no. 3, doi:10.1159/000487294, ISSN 1015-8987, pages 993 - 1002, XP055803667
OPPOSITION- KLIBI et al., "Blood diffusion and Th 1-suppressive effects of galectin-9- containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells", Blood, (20090000), vol. 113, no. 9, doi:10.1182/blood-2008-02-, pages 1957 - 66, XP055538746
OPPOSITION- BARJON et al., "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", Infectious Agents and Cancer, (20120000), vol. 7, no. 1, doi:10.1186/1750-9378-7-16, pages 1 - 11, XP021116920
OPPOSITION- KADOWAKI et al., "Galectin-9 prolongs the survival of septic mice by expanding tim-3-expressing natural killer T cells and PDCA-1+ CDllc+macrophages", Crit Care, (20130000), vol. 17, no. 6, doi:10.1186/cc13147, pages 1 - 11, XP021175303
OPPOSITION- Sun Qiqing, Et Al, "Prognostic and diagnostic signifcance of galectins in pancreatic cancer: a systematic review and meta-analysis", Cancer Cell International, (20191201), vol. 19, no. 309, doi:10.1186/s12935-019-1025-5, pages 1 - 14, XP055803669
OPPOSITION- Cuellar Luis Ernesto et al, "Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience", Infectious Agents and Cancer, (20181201), vol. 13, no. 1, doi:10.1186/s13027-018-0200-y, XP055803450
OPPOSITION- Jiang Jing, Et Al, "Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer", PLoS ONE, (20131201), vol. 8, no. 12, doi:10.1371/journal.pone.0081799, page e81799, XP055803651
OPPOSITION- LHUILLIER, "Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9", PLoS ONE, (20180000), vol. 13, no. 9, doi:10.1371/journal.pone.0202512, pages 1 - 23, XP055538758
OPPOSITION- Hassen Kared, Fabre Thomas, Bédard Nathalie, Bruneau Julie, Shoukry Naglaa H., "Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C", PLoS Pathogens, vol. 9, no. 6, doi:10.1371/journal.ppat.1003422, pages e1003422 - e1003422-18, XP055679515
OPPOSITION- FUJIHARA et al., "Galectin-9 in Cancer Therapy", Recent Pat Endocr Metab Immune Drug Discov., (20130000), vol. 7, no. 2, doi:10.2174/1872214811307020006, pages 130 - 7, XP055494562
OPPOSITION- Yang Jiaxing, Zhu Lin, Cai Yong, Suo Jian, Jin Jingji, "Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer", International journal of oncology, Demetrios A. Spandidos Ed. & Pub, GR, GR, (20140901), vol. 45, no. 3, doi:10.3892/ijo.2014.2494, ISSN 1019-6439, pages 1313 - 1320, XP055803657
OPPOSITION- Fujita Koji, Et Al, "Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo", International journal of oncology, Demetrios A. Spandidos Ed. & Pub, GR, GR, (20150601), vol. 46, no. 6, doi:10.3892/ijo.2015.2941, ISSN 1019-6439, pages 2419 - 2430, XP055803662

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents